CONTEXT: Animal studies suggest that hypophosphatemic rickets (HPR) is associated with muscle function deficits, but it is unknown whether humans with HPR have a muscle disorder. OBJECTIVE: Our objective was to assess calf muscle size and density (an indicator of muscle quality) and lower extremity muscle function in patients with HPR. SETTING: The study was carried out in the outpatient department of a pediatric orthopedic hospital. PATIENTS AND OTHER PARTICIPANTS: Participants included 34 individuals with HPR (6-60 yr; nine males) and 34 age- and gender-matched controls. MAIN OUTCOME MEASURES: Calf muscle parameters (muscle cross-sectional area and density) were measured by peripheral quantitative computed tomography. Lower extremity muscle function (peak force per body weight and peak power per body mass) was measured by jumping mechanography through five tests with different levels of difficulty: multiple two-legged hopping, multiple one-legged hopping, single two-legged jump, chair-rise test, and heel-rise test. RESULTS: Compared with age- and gender-matched controls, patients with HPR had normal muscle size (P = 0.58) but lower muscle density (P = 0.008) and lower peak muscle force and power (P < 0.001 in each test). Muscle function tests were also lower in the subgroup of patients with straight legs (n = 13) than in controls, even though patients with straight legs had higher muscle function test results than patients with severe leg deformities. CONCLUSIONS: The present study suggests that muscle weakness is a clinical feature of HPR. Lower muscle quality and limb deformities contribute to this functional deficit.
CONTEXT: Animal studies suggest that hypophosphatemic rickets (HPR) is associated with muscle function deficits, but it is unknown whether humans with HPR have a muscle disorder. OBJECTIVE: Our objective was to assess calf muscle size and density (an indicator of muscle quality) and lower extremity muscle function in patients with HPR. SETTING: The study was carried out in the outpatient department of a pediatric orthopedic hospital. PATIENTS AND OTHER PARTICIPANTS: Participants included 34 individuals with HPR (6-60 yr; nine males) and 34 age- and gender-matched controls. MAIN OUTCOME MEASURES: Calf muscle parameters (muscle cross-sectional area and density) were measured by peripheral quantitative computed tomography. Lower extremity muscle function (peak force per body weight and peak power per body mass) was measured by jumping mechanography through five tests with different levels of difficulty: multiple two-legged hopping, multiple one-legged hopping, single two-legged jump, chair-rise test, and heel-rise test. RESULTS: Compared with age- and gender-matched controls, patients with HPR had normal muscle size (P = 0.58) but lower muscle density (P = 0.008) and lower peak muscle force and power (P < 0.001 in each test). Muscle function tests were also lower in the subgroup of patients with straight legs (n = 13) than in controls, even though patients with straight legs had higher muscle function test results than patients with severe leg deformities. CONCLUSIONS: The present study suggests that muscle weakness is a clinical feature of HPR. Lower muscle quality and limb deformities contribute to this functional deficit.
Authors: Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli Journal: Nat Rev Endocrinol Date: 2022-04-28 Impact factor: 43.330
Authors: Keith G Avin; Julian A Vallejo; Neal X Chen; Kun Wang; Chad D Touchberry; Marco Brotto; Sarah L Dallas; Sharon M Moe; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2018-03-20 Impact factor: 4.310
Authors: Dennis Lal; Bernd A Neubauer; Mohammad R Toliat; Janine Altmüller; Holger Thiele; Peter Nürnberg; Clemens Kamrath; Anne Schänzer; Thomas Sander; Andreas Hahn; Michael Nothnagel Journal: PLoS One Date: 2016-01-20 Impact factor: 3.240
Authors: Michael J Wacker; Chad D Touchberry; Neerupma Silswal; Leticia Brotto; Chris J Elmore; Lynda F Bonewald; Jon Andresen; Marco Brotto Journal: Front Physiol Date: 2016-05-13 Impact factor: 4.566
Authors: Mary D Ruppe; Xiaoping Zhang; Erik A Imel; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey S Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Munro Peacock; Thomas O Carpenter Journal: Bone Rep Date: 2016-05-13
Authors: Adalbert Raimann; Sarah N Mehany; Patricia Feil; Michael Weber; Peter Pietschmann; Andrea Boni-Mikats; Radka Klepochova; Martin Krššák; Gabriele Häusler; Johannes Schneider; Janina M Patsch; Kay Raum Journal: Front Endocrinol (Lausanne) Date: 2020-06-09 Impact factor: 5.555
Authors: Alison Skrinar; Melita Dvorak-Ewell; Ayla Evins; Carolyn Macica; Agnès Linglart; Erik A Imel; Christina Theodore-Oklota; Javier San Martin Journal: J Endocr Soc Date: 2019-05-07
Authors: Dominik H Pesta; Dimitrios N Tsirigotis; Douglas E Befroy; Daniel Caballero; Michael J Jurczak; Yasmeen Rahimi; Gary W Cline; Sylvie Dufour; Andreas L Birkenfeld; Douglas L Rothman; Thomas O Carpenter; Karl Insogna; Kitt Falk Petersen; Clemens Bergwitz; Gerald I Shulman Journal: FASEB J Date: 2016-06-23 Impact factor: 5.191